PLRZ PLRZ
Company Profile ↓Company Overview
PLRZ (PLRZ) is a publicly traded company listed on with a market capitalization of $18.09M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +63.04% |
| 6 Months: | -28.62% |
| 3 Months: | -20.44% |
| 1 Month: | -26.23% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)41.65 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 34.5% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 895.00K | 635.00K | 1.30M | 5.79M |
| Operating Income | -895.00K | -635.00K | -1.30M | -5.79M |
| EBITDA | -890.00K | -631.00K | -1.18M | -5.44M |
| Interest Expense | - | - | - | - |
| Pretax Income | -779.00K | -600.00K | -1.54M | -3.33M |
| Tax Provision | - | - | - | - |
| Net Income | -779.00K | -600.00K | -1.54M | -3.33M |
| Diluted EPS | -294.35 | -239.27 | -805.20 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 546.00K | 559.00K | 5.55M | 21.44M |
| Current Assets | 51.00K | 54.00K | 2.65M | 12.86M |
| Cash & Equivalents | 36.00K | 4.00K | 2.55M | 1.31M |
| Inventory | - | - | - | - |
| Receivables | - | - | - | - |
| Total Liabilities | 1.45M | 750.00K | 261.00K | 443.00K |
| Current Liabilities | 1.20M | 502.00K | 261.00K | 443.00K |
| Long Term Debt | - | - | - | - |
| Total Debt | 622.00K | 200.00K | - | - |
| Total Equity | -900.00K | -191.00K | 5.29M | 20.99M |
| Shares Outstanding | 2.80K | 2.80K | 2.80K | 1.61M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -1.13M | -537.00K | -1.15M | -4.53M |
| Investing Cash Flow | -3.00K | 0 | 29.00K | -16.53M |
| Financing Cash Flow | 648.00K | 505.00K | 3.67M | 19.81M |
| Capital Expenditure | -3.00K | - | - | -7.00K |
| Free Cash Flow | -1.14M | -537.00K | -1.15M | -4.54M |
| Net Change in Cash | -487.00K | -32.00K | 2.55M | -1.25M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | 86.6% | 314.1% | -29.2% | -15.9% |
| ROCE % | 137.3% | -1,114.0% | -24.6% | -27.6% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PLRZ
Polyrizon shares climb after NASARIX passes key biocompatibility testing (PLRZ)
NASARIX achieves positive biological safety resultsShares of Polyrizon Ltd. (NASDAQ:PLRZ) gained 10% on Friday after the biotechnology company reported successful results from the biocompatibility evaluation programme for its NASARIX Allerg…
Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial
Raanana, Israel, July 02, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced success…
Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial
Raanana, Israel, June 29, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, announced it has receiv…
Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform
Raanana, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the pub…
Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway
New performance and characterization study in collaboration with leading European medical center marks a critical milestone in the validation of the NASARIX™ allergy blocker’s protective barrier function Raanana, Israel, June 15, 2026 (GLOB…
Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology
Raanana, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced that th…
PLRZ — Frequently Asked Questions
What is the current share price of PLRZ?
As of 2026-08-05 17:25 PDT, PLRZ trades at $11.25 on NASDAQ/NYSE. Its 52-week range is $3.13 to $17.17.
What is the market capitalisation of PLRZ?
PLRZ has a market capitalisation of $18.09M on NASDAQ/NYSE.
What is the P/E ratio of PLRZ?
PLRZ trades at a trailing price-to-earnings (P/E) ratio of -0.01. Its price-to-book (P/B) ratio is 0.86.
What is the return on equity (ROE) of PLRZ?
PLRZ has a return on equity (ROE) of -15.89%. Its return on capital employed (ROCE) is -27.56%.
Is PLRZ a good stock to buy?
This page provides a data-driven analysis of PLRZ, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.